FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133223019> ?p ?o ?g. }

• W2133223019 endingPage "4201" @default.
• W2133223019 startingPage "4194" @default.
• W2133223019 abstract "Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non-small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2) disease and with selected IIIB disease. Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after induction.Patients with pathologically proven IIIA(N2) and selected patients with IIIB disease that had medical/functional operability received induction chemotherapy, which consisted of three cycles of cisplatin 50 mg/m(2) on days 1 and 8 and paclitaxel 175 mg/m(2) on day 1 every 21 days, as well as concurrent chemoradiotherapy to 45 Gy given as 1.5 Gy twice daily, concurrent cisplatin 50 mg/m(2) on days 2 and 9, and concurrent vinorelbine 20 mg/m(2) on days 2 and 9. Those patients whose tumors were reevaluated and deemed resectable in the last week of radiotherapy were randomly assigned to receive a chemoradiotherapy boost that was risk adapted to between 65 and 71 Gy in arm A or to undergo surgery (arm B). The primary end point was overall survival (OS).After 246 of 500 planned patients were enrolled, the trial was closed after the second scheduled interim analysis because of slow accrual and the end of funding, which left the study underpowered relative to its primary study end point. Seventy-five patients had stage IIIA disease and 171 had stage IIIB disease according to the Union for International Cancer Control TNM classification, sixth edition. The median age was 59 years (range, 33 to 74 years). After induction, 161 (65.4%) of 246 patients with resectable tumors were randomly assigned; strata were tumor-node group, prophylactic cranial irradiation policy, and region. Patient characteristics were balanced between arms, in which 81 were assigned to surgery and 80 were assigned to a chemoradiotherapy boost. In arm B, 81% underwent R0 resection. With a median follow-up after random assignment of 78 months, 5-year OS and progression-free survival (PFS) did not differ between arms. Results were OS rates of 44% for arm B and 40% for arm A (log-rank P = .34) and PFS rates of 32% for arm B and 35% for arm A (log-rank P = .75). OS at 5 years was 34.1% (95% CI, 27.6% to 40.8%) in all 246 patients, and 216 patients (87.8%) received definitive local treatment.The 5-year OS and PFS rates in randomly assigned patients with resectable stage III non-small-cell lung cancer were excellent with both treatments. Both are acceptable strategies for this good-prognosis group." @default.
• W2133223019 created "2016-06-24" @default.
• W2133223019 creator A5000331988 @default.
• W2133223019 creator A5001369722 @default.
• W2133223019 creator A5012486943 @default.
• W2133223019 creator A5022129852 @default.
• W2133223019 creator A5023902861 @default.
• W2133223019 creator A5036507802 @default.
• W2133223019 creator A5038323479 @default.
• W2133223019 creator A5040777787 @default.
• W2133223019 creator A5043479866 @default.
• W2133223019 creator A5047006205 @default.
• W2133223019 creator A5051124421 @default.
• W2133223019 creator A5052958356 @default.
• W2133223019 creator A5055554357 @default.
• W2133223019 creator A5059687210 @default.
• W2133223019 creator A5060093906 @default.
• W2133223019 creator A5064770442 @default.
• W2133223019 creator A5071494218 @default.
• W2133223019 creator A5071766547 @default.
• W2133223019 creator A5072289854 @default.
• W2133223019 creator A5073827670 @default.
• W2133223019 creator A5075237269 @default.
• W2133223019 creator A5075430350 @default.
• W2133223019 date "2015-12-10" @default.
• W2133223019 modified "2023-10-16" @default.
• W2133223019 title "Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)" @default.
• W2133223019 cites W1870429510 @default.
• W2133223019 cites W1944220675 @default.
• W2133223019 cites W1954745527 @default.
• W2133223019 cites W1967593563 @default.
• W2133223019 cites W1969965083 @default.
• W2133223019 cites W1986794774 @default.
• W2133223019 cites W1989624795 @default.
• W2133223019 cites W1992332581 @default.
• W2133223019 cites W1993312546 @default.
• W2133223019 cites W2025194893 @default.
• W2133223019 cites W2035704169 @default.
• W2133223019 cites W2044673415 @default.
• W2133223019 cites W2059149151 @default.
• W2133223019 cites W2068828048 @default.
• W2133223019 cites W2088720324 @default.
• W2133223019 cites W2097049917 @default.
• W2133223019 cites W2100744367 @default.
• W2133223019 cites W2104504726 @default.
• W2133223019 cites W2104701073 @default.
• W2133223019 cites W2110469369 @default.
• W2133223019 cites W2110996227 @default.
• W2133223019 cites W2128525961 @default.
• W2133223019 cites W2140075859 @default.
• W2133223019 cites W2152939220 @default.
• W2133223019 cites W2156857693 @default.
• W2133223019 cites W2167805334 @default.
• W2133223019 cites W2186446353 @default.
• W2133223019 cites W2600045959 @default.
• W2133223019 cites W2917837889 @default.
• W2133223019 cites W4249552602 @default.
• W2133223019 doi "https://doi.org/10.1200/jco.2015.62.6812" @default.
• W2133223019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26527789" @default.
• W2133223019 hasPublicationYear "2015" @default.
• W2133223019 type Work @default.
• W2133223019 sameAs 2133223019 @default.
• W2133223019 citedByCount "266" @default.
• W2133223019 countsByYear W21332230192015 @default.
• W2133223019 countsByYear W21332230192016 @default.
• W2133223019 countsByYear W21332230192017 @default.
• W2133223019 countsByYear W21332230192018 @default.
• W2133223019 countsByYear W21332230192019 @default.
• W2133223019 countsByYear W21332230192020 @default.
• W2133223019 countsByYear W21332230192021 @default.
• W2133223019 countsByYear W21332230192022 @default.
• W2133223019 countsByYear W21332230192023 @default.
• W2133223019 crossrefType "journal-article" @default.
• W2133223019 hasAuthorship W2133223019A5000331988 @default.
• W2133223019 hasAuthorship W2133223019A5001369722 @default.
• W2133223019 hasAuthorship W2133223019A5012486943 @default.
• W2133223019 hasAuthorship W2133223019A5022129852 @default.
• W2133223019 hasAuthorship W2133223019A5023902861 @default.
• W2133223019 hasAuthorship W2133223019A5036507802 @default.
• W2133223019 hasAuthorship W2133223019A5038323479 @default.
• W2133223019 hasAuthorship W2133223019A5040777787 @default.
• W2133223019 hasAuthorship W2133223019A5043479866 @default.
• W2133223019 hasAuthorship W2133223019A5047006205 @default.
• W2133223019 hasAuthorship W2133223019A5051124421 @default.
• W2133223019 hasAuthorship W2133223019A5052958356 @default.
• W2133223019 hasAuthorship W2133223019A5055554357 @default.
• W2133223019 hasAuthorship W2133223019A5059687210 @default.
• W2133223019 hasAuthorship W2133223019A5060093906 @default.
• W2133223019 hasAuthorship W2133223019A5064770442 @default.
• W2133223019 hasAuthorship W2133223019A5071494218 @default.
• W2133223019 hasAuthorship W2133223019A5071766547 @default.
• W2133223019 hasAuthorship W2133223019A5072289854 @default.
• W2133223019 hasAuthorship W2133223019A5073827670 @default.
• W2133223019 hasAuthorship W2133223019A5075237269 @default.
• W2133223019 hasAuthorship W2133223019A5075430350 @default.
• W2133223019 hasConcept C126322002 @default.
• W2133223019 hasConcept C141071460 @default.
• W2133223019 hasConcept C143998085 @default.

• next